Abbott Medical Lithuania - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 4,946,451 | 5,586,506 | 5,604,786 | 5,391,915 | 6,545,409 | 6,539,792 | 7,440,990 | 7,746,914 |
| Profit before tax | 229,269 | 209,929 | 187,243 | 209,840 | 226,888 | 316,496 | 302,653 | 277,175 |
| Net profit | 186,893 | 167,135 | 159,637 | 169,384 | 197,685 | 277,945 | 228,713 | 226,109 |
| Equity | 3,385,473 | 3,852,902 | 4,012,539 | 4,181,923 | 4,379,608 | 1,757,553 | 1,986,266 | 2,212,375 |
| Liabilities | 33,572 | 59,163 | 41,963 | 65,095 | 107,821 | 102,062 | 128,026 | 135,425 |
| Non-current assets | 32,837 | 3,853 | 2,926 | 2,907 | 2,907 | 28,784 | 5,004 | 61,961 |
| Current assets | 3,398,348 | 3,938,332 | 4,114,260 | 4,347,178 | 4,524,398 | 2,050,049 | 2,156,351 | 2,324,910 |
| Total assets | 3,431,185 | 3,942,185 | 4,117,186 | 4,350,085 | 4,527,305 | 2,078,833 | 2,161,355 | 2,386,871 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 330,543 | 362,068 | 342,432 |
| Social insurance contributions | - | - | - | - | - | 42,599 | 51,845 | 52,455 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +7.1% | +12.9% | +0.3% | -3.8% | +21.4% | -0.1% | +13.8% | +4.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 5.4% | 4.2% | 3.9% | 3.9% | 4.4% | 13.4% | 10.6% | 9.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 5.5% | 4.3% | 4.0% | 4.1% | 4.5% | 15.8% | 11.5% | 10.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 3.8% | 3.0% | 2.8% | 3.1% | 3.0% | 4.3% | 3.1% | 2.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 4.6% | 3.8% | 3.3% | 3.9% | 3.5% | 4.8% | 4.1% | 3.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 1,745,827 | 1,340,751 | 1,401,197 | 1,320,480 | 1,745,442 | 1,634,948 | 1,860,248 | 1,936,729 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Abbott Medical Lithuania - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-03-03 | 2025-03-03 | 0.01 |
| 2025-02-18 | 2025-02-26 | 0.01 |
| 2023-09-18 | 2023-09-24 | 39.97 |
| 2023-07-28 | 2023-07-30 | 39.97 |
| 2023-07-24 | 2023-07-25 | 40.97 |
| 2022-02-17 | 2022-02-27 | 0.01 |
Abbott Medical Lithuania - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Abbott Medical Lithuania, UAB (code 300121108) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year 2025, the company generated revenue of €7.75M and net profit of €226.1K, with a profit margin of 2.9%. Revenue increased by 4.1% year on year and by 18.5% over two years, showing steady top-line expansion. Profit remained positive across the period, though it eased from €277.9K in 2023 to €228.7K in 2024 and €226.1K in 2025, while the margin declined from 4.3% to 3.1% and then to 2.9%. The balance sheet remained conservative: total assets reached €2.39M in 2025, equity €2.21M and liabilities €135.4K, giving an equity ratio of 92.7% and debt-to-equity of 0.06. Return on equity stood at 10.2%, return on assets at 9.5%, and asset turnover at 3.25x. Revenue per employee was €1.94M and profit per employee €56.5K, indicating high productivity.